Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.92 USD
Change Today 0.00 / 0.00%
Volume 216.9K
VICL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

vical inc (VICL) Snapshot

Open
$0.95
Previous Close
$0.92
Day High
$0.96
Day Low
$0.92
52 Week High
07/30/14 - $1.39
52 Week Low
03/23/15 - $0.85
Market Cap
84.0M
Average Volume 10 Days
262.1K
EPS TTM
$-0.19
Shares Outstanding
91.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VICAL INC (VICL)

vical inc (VICL) Related Bloomberg News

View More Bloomberg News

vical inc (VICL) Related Businessweek News

No Related Businessweek News Found

vical inc (VICL) Details

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its product candidates include CyMVectin prophylactic vaccine for cytomegalovirus (CMV), which completed preclinical trial to prevent infection before pregnancy to preclude fetal transmission; and therapeutic vaccine for herpes simplex virus type 2, which is under Phase 1/2 clinical trial to prevent and protect against recurring flare-ups, reduce viral shedding, and transmission. The company, through corporate collaborations, is also developing ASP0113, which is under Phase III clinical trial for prevention of CMV reactivation in stem cell transplant recipients, as well as in Phase II clinical trial for prevention of CMV infection in kidney transplant recipients; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to enhance survival time of dogs with oral melanoma. In addition, Vical Incorporated, through government collaboration, is developing Tetravalent dengue vaccine, a Phase I clinical trial product to prevent dengue disease caused by all four dengue serotypes. Further, it engages in contract manufacturing of plasmid investigational products for various clients. The company was founded in 1987 and is headquartered in San Diego, California.

68 Employees
Last Reported Date: 02/26/15
Founded in 1987

vical inc (VICL) Top Compensated Officers

Chief Executive Officer, President, Acting Ch...
Total Annual Compensation: $821.0K
Chief Accounting Officer and Vice President o...
Total Annual Compensation: $292.2K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $344.8K
Vice President of Vaccine Research
Total Annual Compensation: $337.8K
Compensation as of Fiscal Year 2014.

vical inc (VICL) Key Developments

Vical to Manufacture HIV Vaccines for Clinical Evaluation by Public-Private Partnership Initiative

Vical Incorporated announced that it has entered into a $4 million contract with the IPPOX Foundation to manufacture HIV-antigen plasmid DNA as a component of vaccine regimens to be evaluated in clinical trials for the prevention of HIV infection. IPPOX is a Swiss non-profit foundation that participates in the conduct of HIV vaccine clinical trials under the auspices of the Pox-Protein Public-Private Partnership (P5), funded by the Bill & Melinda Gates Foundation and the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The new contract builds upon Vical's 2010 agreement with IPPOX to manufacture plasmid DNA for HIV vaccine clinical trials and recent encouraging clinical data. The plasmids manufactured by Vical are expected to be used as priming components of prime/boost vaccine regimens that will be evaluated in additional Phase 1 studies and potentially in a Phase 2b clinical trial to follow. Vical expects material delivery to begin in the fourth quarter of 2015. Additionally, Vical has signed a Memorandum of Understanding with the Gates Foundation to cooperate on HIV vaccine projects established under the P5 partnership. P5 seeks to advance and potentially license HIV vaccine candidates that have the potential to achieve a broad public health impact. Core funding for P5 is provided by the foundation and the NIH, and current partners include the foundation, U.S. National Institute of Allergy and Infectious Diseases/Division of AIDS, the HIV Vaccine Trials Network, Novartis Vaccines and Diagnostics, Sanofi Pasteur, the South Africa Medical Research Council, the U.S. Military HIV Research Program (MHRP), GlaxoSmithKline, and Centre Hospitalier Universitaire Vaudois (CHUV).

Vical Incorporated Announces Preclinical Data for Congenital CMV DNA Vaccine at International Conference

Vical Incorporated announced that Michael McVoy, Ph.D., Professor of Pediatrics at Virginia Commonwealth University, presented data from preclinical studies testing several combinations of Vaxfectin®- formulated glycoprotein-B (gB)-encoding DNA vaccines for neutralizing antibody responses. Vaxfectin is Vical's novel, proprietary cationic lipid-based adjuvant and is used in CyMVectin™, the company's congenital CMV vaccine candidate. The studies found that vaccines encoding gB provided both fibroblast and epithelial entry neutralizing titers that were comparable to those observed in sera from humans with naturally-acquired CMV infections. The data suggest that CyMVectin has the potential to induce neutralizing antibodies against a broad range of cells.

Vical Incorporated - Special Call

Vical Incorporated - Special Call

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VICL:US $0.92 USD 0.00

VICL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Argos Therapeutics Inc $8.04 USD +0.47
Dynavax Technologies Corp $20.18 USD -0.33
GenVec Inc $2.37 USD -0.05
Inovio Pharmaceuticals Inc $8.46 USD +0.04
Peregrine Pharmaceuticals Inc $1.32 USD +0.01
View Industry Companies
 

Industry Analysis

VICL

Industry Average

Valuation VICL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.5x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VICAL INC, please visit www.vical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.